17Dec
Related Posts
22Nov
The Nuclear Renaissance with Cauldron Energy
22 Nov 2023 - Jonathan Fisher serves as the CEO of Cauldron Energy (ASX:CXU). Cauldron Energy is primarily engaged in exploration activities, with a specific focus on uranium and critical minerals in the Western Australia region.
Read More
16Dec
Sienna Cancer Diagnostics (ASX:SDX) capital raising
16 Dec 2019 - Sienna Cancer Diagnostics Limited (ASX:SDX) Managing Director and CEO Carl Stubbings talks about the company's capital raising and co-development of tests using its SIEN-NET liquid biopsies platform technology.
Read More
29Mar
Telix Pharmaceuticals (ASX:TLX) – harnessing radiation to see and treat a range of oncology targets
29 Mar 2021 - Telix Pharmaceuticals Limited (ASX:TLX) Chief Business Officer Dr David Cade talks about the company's clinical programs, including approvals, partnerships and significant value events anticipated in 2021.
Read More
04Dec
Xref (ASX:XF1) FY19 results & outlook
04 Dec 2019 - Xref Limited (ASX:XF1) CEO & Co-Founder, Lee-Martin Seymour, talks about the company's candidate reference checking solution for HR departments, partner integration and expansion.
Read More
21Sep
RIU Good Oil & Gas Conference Q&A – Phil McNamara of Emperor Energy (ASX:EMP)
21 Sep 2023 - Phil McNamara - Director - Emperor Energy (ASX:EMP) is a diversified energy company with upstream and downstream assets in Australia. The company’s strategic asset Vic/P47 in the Gippsland Basin next to the BHP/ExxonMobil Kipper field.
Read More
21Jun
Sayona’s vertically integrated NAL NPV now exceeds A$5bn
21 Jun 2023 - Sayona Mining Limited (ASX:SYA) Finance Manager Dougal Elder discusses key takeaways from the recent lithium carbonate study, improvement in operation total value, and steps to get to first production in 2026.
Read More
16Jun
Zelira Therapeutics (ASX:ZLD) developing clinically validated medicinal cannabis products
16 Jun 2020 - Zelira Therapeutics Limited (ASX:ZLD) Managing Director Ex USA, Dr Richard Hopkins talks about the company's pipeline of products in clinical development targeting insomnia, chronic pain and autism, its model for rapid commercialisation, its go-to-market strategy and first revenues from US licensing partners.
Read More
01Jun
OncoSil Medical (ASX:OSL) gets CE approval
01 Jun 2020 - OncoSil Medical Limited (ASX:OSL) Managing Director and CEO Daniel Kenny talks about the significance of the company's CE Marking approval for its lead product OncoSil, which helps treat pancreatic, liver and biliary duct cancer.
Read More
01May
Acorn Capital microcap and emerging company specialist
01 May 2020 - Acorn Capital, Head of Portfolio Implementation and Portfolio manager (Healthcare and Biotechnology sectors) Paul Palumbo looks the microcap sector and the recent market sell off and discusses the outlook for next 6 months and longer term.
Read More
03Feb
Nyrada (ASX:NYR) collaboration with Walter Reed and UNSW
03 February 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar talks about the company's collaboration agreement with the Walter Reed Army Institute of Research and UNSW into the study of a first-ever pharmaceutical treatment for traumatic brain injury, a top health priority for the military.
Read More